D. Bron MD, PhD

P2.04 Immune impairments of the multiple myeloma bone-marrow mesenchymal stromal cells

P2.05 Global HDAC enzymatic activity is a strong marker of poor prognosis in Chronic Lymphocytic Leukemia

P2.17 The respective value of the G8 screening and the Comprehensive Geriatric Assessment (CGA) for the identification of vulnerable older patients with hematological malignancies susceptible to benefit from chemotherapy

P4.18 A long (GT)n repeat genetic variant in the promoter region of heme oxygenase-1 is associated with severe graft-versus-host disease

P2.21 Post-Transplant Lymphoproliferative Disorder following solid organ transplantation

A phase I/II single centre study of haploidentical transplantation combined with G-GSF, or GM-CSF, and escalating DLI in high-risk patients with no matched donors

Summary

In 1999, we decided to start a phase I/II study of haploidentical transplantation for high-risk patients. The aim of the work was to implement a strategy to accelerate and strengthen the immune reconstitution by using nonspecific manipulation post-transplant and by developing specific strategies directed against viral antigens. The goal was to increase the graft-versus-leukemia effect without inducing or aggravating the deleterious graft-versus-host disease. The conditioning regimen, adapted to our group of patients, remained the same throughout. Importantly, the first recruited patients were in refractory disease, over time we were referred less advanced patients (complete remission 2 or more). There were 45 patients, all at high-risk, among which 27 were in refractory relapse. We questioned the importance of post-transplant growth factors policy and the influence of donor lymphocyte infusion. Because of the conditioning, transplant-related mortality was low at 3 months, but thereafter changed unfavourably when using granulocyte macrophage-colony stimulating factors in an increased incidence of acute graft-versus-host disease. As a whole the long-term survival of the patients was poor (18%) but improved a lot when transplanted patients were in complete remission (leukaemia-free survival of 39% at five years). Regarding the use of growth factors and donor lymphocyte infusion, granulocyte macrophage-colony stimulating factors with donor lymphocyte infusion induced a very high transplant-related mortality due to a high rate of severe graft-versus-host disease, while the combination of granulocyte colony-stimulating factors and a moderate dose of donor lymphocyte infusion was much safer but didn’t overcome the high relapse rate in refractory patients. The combination of granulocyte colony-stimulating factors and donor lymphocyte infusion might nonetheless be sufficient to decrease the infection rate in patients transplanted in complete remission. The use of granulocyte macrophage-colony stimulating factors leads to an unacceptable lethal graft-versus-host disease rate. The 39% at five years leukaemia-free survival in patients in complete remission compares favourably with what can be achieved with matched unrelated donors in complete remission 2 or more.

(BELG J HEMATOL 2013;4(4): 151–160)

Treatment of peripheral T-cell lymphomas: recommendations of the Belgian Hematological Society (BHS)

Summary

The sub-committee on lymphoproliferative disorders of the Belgian Hematological Society has met several times to prepare guidelines on the management of patients with peripheral T-cell lymphomas. Each panellist’s expert provided interpretation of the evidence, based on literature review and personal experience. The available evidence was systematically discussed prior to formulating recommendations. A systematic approach to obtain consensus of expert opinion was used. After each meeting, the draft guideline was circulated to all experts for comment and approval. The present guidelines focus on general management of peripheral T-cell lymphomas with special emphasis on more specific disease-adapted strategies.

(BELG J HEMATOL 2013;4(3):90–101)